Jan 22, 2021
Prof. Dr. Olaf Groß, principal invetigator in the CRC 1160 (C02N), receives ERC proof of concept funding for his project IMMUNOSTIM. He and his team are testing whether a class of new immune-activating agents, that they have discovered, can increase the effectiveness of cancer immunotherapies or vaccines against infectious diseases. As part of the funding, they discovered a new class of small molecules that act like a turbo booster for the immune system.
